SecBot SecBot
8-K ·Filed Aug 13, 2026

CRMD

CorMedix Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001410098-26-000054
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth is driven by the Melinta acquisition and DefenCath expansion, but Q2 revenue ($101.9M) declined sequentially from Q1 ($127.4M) due to a non-recurring $9M sales allowance adjustment in Q1. The raised EBITDA guidance and new LDO contract are positive, but the sequential revenue drop and pending TDAPA expiration warrant monitoring. Watch for REZZAYO sNDA submission in Q3 and the LDO pilot start.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

CRMD drug pipeline →

rezafungin

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
Next catalyst
NDA filing · 2026

What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.

Price Chart

Loading chart...

Executive Summary

CorMedix reported Q2 2026 consolidated revenue of $101.9M and net income of $26.0M ($0.33 basic EPS), compared to $39.7M revenue and $19.8M net income in Q2 2025. The company maintained full-year revenue guidance of $325-$345M and raised adjusted EBITDA guidance to $125-$140M. DefenCath sales of $66.1M and Melinta portfolio contributions of $35.8M drove results, while the company signed a new supply agreement with a large dialysis operator covering all top 5 U.S. providers.

Key Financial Metrics

EPS
$0.33
est $0.26 · +26.9%
Revenue
$101.9M
est $96.0M · +6.2% · +156.5% YoY
Rating
in line
Guidance
$325M-$345M
maintained
Gross Margin
75.7%

Key Facts

  • Q2 2026 consolidated revenue of $101.9M vs $39.7M in Q2 2025
  • Net income of $26.0M ($0.33 basic EPS) vs $19.8M ($0.29 basic EPS) in Q2 2025
  • Adjusted EBITDA of $58.7M vs $22.4M in Q2 2025
  • Full-year 2026 revenue guidance maintained at $325-$345M
  • Full-year adjusted EBITDA guidance raised to $125-$140M from $115-$135M
  • DefenCath sales of $66.1M; Melinta portfolio contributed $35.8M
  • New multi-year commercial supply agreement with a Large Dialysis Operator covering all top 5 U.S. providers
  • Cash and short-term investments of $256.7M at June 30, 2026
  • FDA submission of REZZAYO sNDA for prophylaxis expected in Q3 2026

Financial Impact

Revenue grew 156% YoY to $101.9M; net income increased 31% to $26.0M; adjusted EBITDA rose 162% to $58.7M

revenuenet incomeadjusted EBITDAcash position

Risk Factors

  • Sequential revenue decline from $127.4M in Q1 to $101.9M in Q2
  • Pending TDAPA reimbursement expiration for DefenCath
  • Ongoing securities litigation with $4.2M insurance reimbursement partially offsetting G&A
  • Dependence on Melinta acquisition integration and pipeline execution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001410098-26-000054
Document: crmd-20260813.htm0001410098-26-000054
Document: 0001410098-26-000054-index-headers.html0001410098-26-000054
Document: 0001410098-26-000054-index.html0001410098-26-000054
Document: 0001410098-26-000054.txt0001410098-26-000054
8-K Data (Synthetic)0001410098-26-000054

Track record

21 reports on CRMD

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
  2. Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  3. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
  4. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
  6. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  7. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
  9. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
  10. Aug 13, 202613w ago 8-K Neutral 5/10 Viewing No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026